Navigation Links
CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of,Action for Ranexa

-- New Preclinical Information May Correlate with Clinical HbA1c Reductions Observed in Phase 3 CARISA and MERLIN TIMI-36 Clinical Trials --

PALO ALTO, Calif., July 9, 2007 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that researchers have completed preliminary preclinical studies showing that ranolazine increased glucose stimulated insulin secretion in pancreatic beta cells. In separate experiments using preclinical models of insulin resistance, ranolazine also improved glucose homeostasis.

These data could illustrate an underlying first in class mechanism of action for the statistically significant reductions in HbA1c levels observed with Ranexa in cardiovascular patients with diabetes from the phase 3 CARISA (n=189 with angina and diabetes) and MERLIN TIMI-36 (n=2,220 with acute coronary syndromes and diabetes) clinical trials.

In CARISA (Combination Assessment of Ranolazine in Stable Angina), Ranexa (ranolazine extended release tablets) reduced HbA1c levels by an average of up to 0.7 percentage points in angina patients with diabetes. The reduction in HbA1c was not associated with increased hypoglycemia.

"Preclinical studies have shown that Ranexa inhibits the late sodium current in cardiac cells. Potentially, the sodium channels present in pancreatic beta cells may play a role in the secretion of insulin," said Luiz Belardinelli, M.D., senior vice president of pharmacological translational and biomedical research and a distinguished fellow of cardiovascular science at CV Therapeutics.

The company plans to submit data from these new preclinical experiments for publication later this year.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of ca
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
4. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
5. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
6. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
7. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
8. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
9. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
10. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
11. Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
Post Your Comments:
(Date:8/28/2015)... Denmark and ATLANTA , ... 2015 the US Food and Drug Administration (FDA) cleared the ... Disorder in adult patients who have failed to receive satisfactory ... is a non-invasive technique for stimulating neural tissue in the ... Depressive Disorder. The procedure has been proven safe and effective ...
(Date:8/28/2015)... , August 28, 2015 Insights- ... seamlessly connects people, technologies and care protoc ols across ... and the cost of healthcare delivery   ... presence at  ESC Congress 2015 , where the company is ... EchoNavigator and IntelliSpace Cardiovascular, that connect people and technology with ...
(Date:8/27/2015)... -- Biosimilars are not generics and the Biologics ... Drug Administration (FDA) for recognizing that each biosimilar ... issued today. The FDA,s draft guidance on nonproprietary ... for biological products to bear a nonproprietary name ... the agency,s thinking that "there is a need ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... Misonix, Inc. (NASDAQ: MSON ), ... markets innovative therapeutic ultrasonic products worldwide for wound ... surgical and medical applications, today announced plans to ... results on Wednesday, November 9, 2011.  Michael A. ...
... 2011 Allied Healthcare Products, Inc. (NASDAQ: AHPI ) ... sales. Allied,s net loss for the first quarter of ... cents per basic and diluted share, versus a loss of about ... year,s first quarter. Allied,s sales for the quarter ending ...
Cached Medicine Technology:Misonix Schedules First Quarter Fiscal 2012 Financial Results Conference Call; November 9, 2011 at 4:30 p.m. Eastern 2Allied Healthcare Products Reports First Quarter Loss on Sales Decline 2Allied Healthcare Products Reports First Quarter Loss on Sales Decline 3Allied Healthcare Products Reports First Quarter Loss on Sales Decline 4
(Date:8/28/2015)... ... August 28, 2015 , ... CARF ... its adolescent residential, counseling, day treatment and intensive family based services. , By ... for quality and its pursuit of excellence. As a nonprofit charity for more ...
(Date:8/28/2015)... ... 2015 , ... Northridge dentists Dr. Elyson and Dr. Assili are ... can currently receive a one hour treatment of this teeth whitening option. Zoom ... number of unique features that can turn teeth up to nine shades whiter. Effective ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... is dedicated to distributing health information technology innovation to transform quality and efficiency ... of the survey will be de-identified and aggregated before being publicly shared to ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... top 5 millionaire dating sites . According to the listings, MillionaireMatch.com ... best in this category. , A spokesperson of Top5MillionaireDatingSites.com said, “This ...
(Date:8/28/2015)... ... August 28, 2015 , ... A complimentary webinar offered by healthcare consulting and ... (CMS) proposal to mandate bundled payments through the Comprehensive Care for Joint ... Day: Comprehensive Care for Joint Replacement,” takes place at 12 noon EDT on Wednesday, ...
Breaking Medicine News(10 mins):Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:PYA Offers Complimentary CCJR Webina — Game On 2Health News:PYA Offers Complimentary CCJR Webina — Game On 3
... today announced that Glenn A. Oclassen, President & Chief ... Development in a,Changed Environment" at the RBC Capital Markets ... Times Square on Thursday, December 13, 2007,at 10:00 AM ... by Ken Trbovich, Vice,President, Capital Markets at RBC, and ...
... Worsening State Budget Picture, Ongoing Medicaid,Funding Crisis Cited, ... Payment Advisory Commission,s (MedPAC) draft recommendation that,skilled nursing ... for 2009, the Alliance for Quality Nursing Home ... the mark" in terms of,providing Congress with the ...
... or more servings of green salad a week and working ... nonsmokers alike may be able to substantially reduce the risk ... Texas M. D. Anderson Cancer Center. , "This is the ... and physical activity on the possibility of developing lung cancer," ...
... Dec 7 Bond,Laboratories, Inc. (OTC Bulletin Board: BNDB), ... to file with the NASD to implement,a 2-for-1 forward ... shareholders as of the record date will receive,two (2) ... own. For,example, shareholders owning 5,000 shares prior to the ...
... her 2002 book "Growing,Up X," Ilyasah Shabazz describes growing up ... recently, Ms. Shabazz has delved deeper,into her family tree, discovering ... December 9 - 14, Ms. Shabazz will visit her ancestral ... hosted by Malaria No More, an,organization working to end malaria-related ...
... The Board of Directors of the,Pittsburgh Life Sciences ... company formation and business growth,services to the region,s ... nomination of Dr. D. Lansing Taylor as the ... In making the announcement, outgoing Co-Chairs Mark Nordenberg ...
Cached Medicine News:Health News:Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference 2Health News:MedPAC Again Fails to Evaluate Overall Economic Conditions in Assessing SNF Funding Requirements 2Health News:MedPAC Again Fails to Evaluate Overall Economic Conditions in Assessing SNF Funding Requirements 3Health News:M. D. Anderson research links diet, gardening and lung cancer risk 2Health News:Malcolm X Daughter Travels to Ancestral Home; Joins Muslim-American Leadership to Fight Malaria in Mali 2Health News:The Pittsburgh Life Sciences Greenhouse Announces New Chairman of the Board 2Health News:The Pittsburgh Life Sciences Greenhouse Announces New Chairman of the Board 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: